---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-017293"
form_type: "8-K"
ticker: "CTNM"
cik: "0001855175"
company_name: "Contineum Therapeutics, Inc."
filed_at: "2024-05-16T23:59:59+00:00"
generated_at: "2026-06-01T21:43:14.254270+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Contineum Q1 2024 cash $117.9M; IPO net proceeds $108M extend runway to 2027

## Summary
- Cash and securities $117.9M at March 31; proforma cash (incl. IPO) $225.9M.
- R&D expenses $7.8M vs $3.6M YoY; increase driven by product candidate development.
- Completed IPO in April 2024; net proceeds $108.0M, extending cash runway to end of 2027.
- Initiated Phase 2 trial of PIPE-307 in RRMS; J&J partner plans Phase 2 in depression in 2024.
- Nominated third development candidate CTX-343 (LPA1R antagonist); IND submission expected in 2025.

## SEC filing metadata
- accession: 0001437749-24-017293
- form_type: 8-K
- ticker: CTNM
- cik: 0001855175
- company_name: Contineum Therapeutics, Inc.
- filed_at: 2024-05-16T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855175/000143774924017293/0001437749-24-017293-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855175/000143774924017293/cont20240417_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-017293
- JSON: https://secwatch.observer/filing/0001437749-24-017293.json
- Plain text: https://secwatch.observer/filing/0001437749-24-017293.txt

## Key facts
- Earnings Releases
  Contineum Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2024.
  - Period: the first quarter ended March 31, 2024
  - Result: reported results
  source text: today reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855175/000143774924017293/0001437749-24-017293-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.